Novo Nordisk Logo

Novo Nordisk

Novo Nordisk Logo
Novo Nordisk

Complaints

3 complaints
Search in results...

Novo Nordisk Delays Wegovy Defect Investigation for 200 Days

I purchased Novo Nordisk's Wegovy medication from a pharmacy in mid-March. Because we suspected that the product was def...

Ozempic Injection Pen Stops Working Due to Suspected Manufacturing Defect

I purchased an Ozempic 0.25 mg prefilled injection pen with a valid prescription from Peker Pharmacy in Avcılar, Istanbu...

Ozempic Pen Suspected of Delivering Incorrect Doses for Three Weeks

I purchased a Novo Nordisk Ozempic 0.25 mg injection pen from Sarı Pharmacy in Darıca on July 29, paying $210. I adminis...

Ozempic Pen Suspected of Delivering Incorrect Doses for Three Weeks
Ozempic Pen Suspected of Delivering Incorrect Doses for Three Weeks
Ozempic Pen Suspected of Delivering Incorrect Doses for Three Weeks
Ozempic Pen Suspected of Delivering Incorrect Doses for Three Weeks

Brand Overview: Novo Nordisk

Novo Nordisk is a leading global healthcare and pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company operates under Novo Nordisk A/S, with majority voting control held by Novo Holdings A/S on behalf of the Novo Nordisk Foundation. The company is best known for developing therapies for diabetes, obesity, and other serious chronic conditions.

Contact Info

Global Corporate Phone: +45 4444 8888

US Customer Care Phone: +1 (800) 727-6500

Customer Support Email: Direct global support is primarily handled through the localized online inquiry forms on the official website; regional divisions also provide specific email contacts such as [email protected] or via regional NovoCare patient portals.

Industry and Operations

Novo Nordisk operates in the pharmaceutical and life sciences sector, specializing in the research, manufacturing, and marketing of biological medicines and medical injection technologies.

  • Diabetes Management: Developing and supplying insulin therapies and GLP-1 receptor agonist medications, such as Ozempic and Rybelsus.
  • Obesity Care: Producing weight-management prescription treatments, including Wegovy and Saxenda.
  • Rare Blood and Endocrine Disorders: Formulating specialized pharmaceuticals for hemophilia, growth hormone deficiencies, and related metabolic conditions.
  • Delivery Systems: Designing pre-filled and reusable injection pens, such as FlexTouch and NovoPen, designed for patient self-administration.

User Sentiment

Overall user feedback reflects significant consumer frustration, particularly regarding medication accessibility, device reliability, and navigating customer assistance programs.

  • Supply Shortages and Fulfillment Delays: Frequent reports of limited pharmacy inventory and prolonged delays in securing high-demand GLP-1 medications, disrupting scheduled treatment regimens.
  • High Pricing and Savings Card Difficulties: Consumer dissatisfaction over retail prescription costs, insurance coverage denials, and obstacles when trying to apply copay coupons or discount vouchers.
  • Injection Device Malfunctions: Complaints about auto-injector pens jamming, failing to dispense the full liquid dose, or registering dial errors, resulting in wasted medication.
  • Customer Service Delays: Difficulty reaching responsive support representatives and protracted waiting periods for replacement vouchers after reporting defective pens.
  • Adverse Side Effects: Concerns raised by users experiencing gastrointestinal symptoms or unexpected adverse events, alongside calls for clearer guidance during dosage adjustments.

Share Your Experience

If you have experienced issues with Novo Nordisk, you are not alone. Share your experience or file a complaint on Xolvie to let your voice be heard.

Contact